Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78(1):76-80.

View in: PubMed